Condition
Exocrine Pancreatic Cancer
Total Trials
4
Recruiting
2
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04011982RecruitingPrimary
PATAKESS Protocol : Clinical and Biological Analysis of Exocrine Pancreatic Tumors
NCT03485209Phase 2Active Not Recruiting
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT04930991Early Phase 1RecruitingPrimary
High Dose Omeprazole in Patients With Pancreatic Cancer
NCT01020006Phase 2Completed
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Showing all 4 trials